Ars Pharmaceuticals Stock Market Value
| SPRY Stock | 8.87 0.30 3.27% |
| Symbol | ARS |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARS Pharmaceuticals. If investors know ARS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ARS Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 14.716 | Return On Assets | Return On Equity |
Understanding ARS Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects ARS's accounting equity. The concept of intrinsic value - what ARS Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push ARS Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between ARS Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ARS Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, ARS Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
ARS Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ARS Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ARS Pharmaceuticals.
| 12/03/2025 |
| 03/03/2026 |
If you would invest 0.00 in ARS Pharmaceuticals on December 3, 2025 and sell it all today you would earn a total of 0.00 from holding ARS Pharmaceuticals or generate 0.0% return on investment in ARS Pharmaceuticals over 90 days. ARS Pharmaceuticals is related to or competes with GH Research, Nanobiotix, Arbutus Biopharma, LENZ Therapeutics, Savara, Rezolute, and Kura Oncology. ARS Pharmaceuticals is entity of United States More
ARS Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ARS Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ARS Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.99 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 32.13 | |||
| Value At Risk | (5.94) | |||
| Potential Upside | 6.82 |
ARS Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ARS Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ARS Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use ARS Pharmaceuticals historical prices to predict the future ARS Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0134 | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0109 |
ARS Pharmaceuticals March 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0134 | |||
| Market Risk Adjusted Performance | 0.0209 | |||
| Mean Deviation | 3.12 | |||
| Semi Deviation | 3.93 | |||
| Downside Deviation | 3.99 | |||
| Coefficient Of Variation | 14957.39 | |||
| Standard Deviation | 4.52 | |||
| Variance | 20.43 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.0109 | |||
| Maximum Drawdown | 32.13 | |||
| Value At Risk | (5.94) | |||
| Potential Upside | 6.82 | |||
| Downside Variance | 15.95 | |||
| Semi Variance | 15.47 | |||
| Expected Short fall | (3.58) | |||
| Skewness | 0.8621 | |||
| Kurtosis | 4.67 |
ARS Pharmaceuticals Backtested Returns
ARS Pharmaceuticals secures Sharpe Ratio (or Efficiency) of close to zero, which signifies that the company had a close to zero % return per unit of risk over the last 3 months. ARS Pharmaceuticals exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm ARS Pharmaceuticals' mean deviation of 3.12, and Risk Adjusted Performance of 0.0134 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.85, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ARS Pharmaceuticals will likely underperform. At this point, ARS Pharmaceuticals has a negative expected return of -0.019%. Please make sure to confirm ARS Pharmaceuticals' value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to decide if ARS Pharmaceuticals performance from the past will be repeated at future time.
Auto-correlation | -0.74 |
Almost perfect reverse predictability
ARS Pharmaceuticals has almost perfect reverse predictability. Overlapping area represents the amount of predictability between ARS Pharmaceuticals time series from 3rd of December 2025 to 17th of January 2026 and 17th of January 2026 to 3rd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ARS Pharmaceuticals price movement. The serial correlation of -0.74 indicates that around 74.0% of current ARS Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.74 | |
| Spearman Rank Test | -0.7 | |
| Residual Average | 0.0 | |
| Price Variance | 0.31 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ARS Stock Analysis
When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.